Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study.

Simona Simone Virginia Pronzo Francesco Pesce Davide Fiore Bavaro Barbara InfanteSilvia MercuriAnnalisa Schirinzi Antonella Panaro Eleonora Conte Alessandra Belati Dario Troise Paola Pontrelli Francesca Conserva Pasquale GalloMaddalena PanicoMarco Spilotros Giuseppe Lucarelli Annalisa Saracino Giovanni Stallone Francesca Di Serio Pasquale Ditonno Loreto Gesualdo

Published in: Journal of nephrology (2024)

In conclusion, our study showed that tixagevimab/cilgavimab 150/150 mg is effective and safe in preventing infection and severe disease when administered to patients with weak or no response to COVID-19 vaccine.

Keyphrases

coronavirus disease
sars cov
clinical trial
double blind
drug induced
respiratory syndrome coronavirus